Cargando…

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC

c-Met is a receptor tyrosine kinase with no commercially available product despite being a pivotal target in cancer progression. Unlike other c-Met inhibitors that fail clinically, ABN401 is a newly synthesized c-Met inhibitor that is not potentially degraded by aldehyde oxidase (AO) in human liver...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Nam Ah, Hong, Sungyoul, Kim, Ki Hyun, Choi, Du Hyung, Kim, Joo Seok, Park, Kyung Eui, Choi, Jun Young, Shin, Young Kee, Jeong, Seong Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076440/ https://www.ncbi.nlm.nih.gov/pubmed/32028611 http://dx.doi.org/10.3390/pharmaceutics12020121

Ejemplares similares

Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer
por: Kim, Jooseok, et al.
Publicado: (2020)

Genes co-amplified with ERBB2 or MET as novel potential cancer-promoting genes in gastric cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2017)

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
por: Park, Chi Hoon, et al.
Publicado: (2016)

Solubility Determination of c-Met Inhibitor in Solvent Mixtures and Mathematical Modeling to Develop Nanosuspension Formulation
por: Ravi, Maharjan, et al.
Publicado: (2021)

MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report
por: Choi, Wonyoung, et al.
Publicado: (2022)

A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
por: Fujita, Ryo, et al.
Publicado: (2020)

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

MET-Amplified Intramucosal Gastric Cancer Widely Metastatic after Complete Endoscopic Submucosal Dissection
por: Lee, Dakeun, et al.
Publicado: (2015)

c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer
por: Kang, Chung Hyo, et al.
Publicado: (2021)

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study
por: Seto, Takashi, et al.
Publicado: (2021)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
por: Wang, Kaiwen, et al.
Publicado: (2023)

MET Expression in Sporadic Renal Cell Carcinomas
por: Choi, Jong Sun, et al.
Publicado: (2006)

Expression of c-MET in Invasive Meningioma
por: Yun, Sumi, et al.
Publicado: (2015)

Renoprotective effects of a novel cMet agonistic antibody on kidney fibrosis
por: Kim, Yong Chul, et al.
Publicado: (2019)

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)
por: Heo, Mi Hwa, et al.
Publicado: (2017)

c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma
por: Kim, Ha-Jeong, et al.
Publicado: (2016)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Cai, Boning, et al.
Publicado: (2021)

Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
por: Kim, Yong Chul, et al.
Publicado: (2018)

The Regenerative Effects of c-Met Agonistic Antibodies in Vocal Fold Atrophy
por: Choi, Hyunsu, et al.
Publicado: (2022)

c-Met inhibitors
por: Mughal, Anum, et al.
Publicado: (2013)

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2021)

Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR
por: Kim, Seongjae, et al.
Publicado: (2023)

Urinary cMet as a prognostic marker in immunoglobulin A nephropathy
por: An, Jung Nam, et al.
Publicado: (2020)

Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)

A glioneuronal tumor with CLIP2-MET fusion
por: Chowdhury, Tamrin, et al.
Publicado: (2020)

Role of HGF/c-Met in Serum-Starved ARPE-19 Cells
por: Jun, Eun Jung, et al.
Publicado: (2007)

Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer
por: Lin, Xiaoting, et al.
Publicado: (2019)

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
por: Martin, Valentina, et al.
Publicado: (2019)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Yoshimura, Katsuhiro, et al.
Publicado: (2021)

Clinical and pathological characteristics of 11 NSCLC patients with c-MET exon 14 skipping
por: Chen, Hualin, et al.
Publicado: (2022)

Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy
por: Kim, Ki-Hyun, et al.
Publicado: (2017)

Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification
por: Ding, Caixia, et al.
Publicado: (2023)

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC
por: Jie, Guang-Ling, et al.
Publicado: (2023)

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer
por: Shitara, Kohei, et al.
Publicado: (2017)

Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation
por: Owusu, Benjamin Y., et al.
Publicado: (2017)

Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells
por: Jo, Eun Byeol, et al.
Publicado: (2019)

Critical Role of MetR/MetB/MetC/MetX in Cysteine and Methionine Metabolism, Fungal Development, and Virulence of Alternaria alternata
por: Gai, Yunpeng, et al.
Publicado: (2021)

Met–HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells
por: Stern, Yaakov E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i11m173egd5s837lj8bmapvvbs